

	Areas / Sub-Area	Topic number	Topic title	Funding scheme	Ceiling EURO million	SME	Project officer	Unit	
P I L L A R 1	1.1. HIGH-THROUGHPUT RESEARCH		CLOSED						
	1.2. DETECTION, DIAGNOSIS & MONITORING	1.2-1	Development of technologies with a view to patient group stratification for personalised medicine applications	CP-SME	6	SME (30%)	Jean-Luc Sanne	F5	
	1.3. SUITABILITY, SAFETY, EFFICACY OF THERAPIES		CLOSED						
	1.4. INNOVATIVE THERAPIES	1.4-1	Innovative approaches to solid organ transplantation	CP-FP	6	SME (15%)	Charles Kessler/ Juergen Sautter	F4	
		1.4-2	Medical technology for transplantation and bioartificial organs	CP-SBIR like	6	SME (50%)	Bernd Rainer/Torbjoern Ingemansson/Charles Kessler	F4	
1.4-3		Innovative strategies for translation of stem cell based therapies in regenerative medicine (European Union-Australia cooperation)	CP-FP	6	SME (15%)	Charles Kessler/Arnd Hoeveler	F4		
1.4-4		Targeted nucleic acid delivery as innovative therapeutic or prophylactic approach	CP-FP	6	industry (30%)	David Gancberg	F4		
P I L L A R 2	2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES	2.1.1. Large scale data gathering	2.1.1-1-A	Support for the international rare disease research	SA	2		Catherine Berens	F5
			2.1.1-1-B	Clinical utility of -omics for better diagnosis of rare diseases	CP-IP	12	industry (30%)	Patrik Kolar	F5
			2.1.1-1-C	Databases, biobanks and 'clinical bio-informatics' hub for rare diseases.	CP-IP	12		Iiro Eerola	F5
			2.1.1-2	Validation of -omics based biomarkers for diseases affecting the elderly	CP-IP-SME	12	SME (30%)	Jean-Luc Sanne	F5
		2.1.1-3	Statistical methods for collection and analysis of -omics data	CP-SME	6	SME (15%)	Philippe Jehenson	F5	
	2.1.2. Systems Biology	2.1.2-1	Systems medicine: SME-driven research applying systems biology approaches to address medical and clinical needs (innovation projects)	CP-SME	3	SME (30%)	Bernard Mulligan/Christina Kyriakopoulou	F4	
		2.1.2-2	Systems medicine: Applying systems biology approaches for understanding multifactorial human diseases and their co-morbidities	CP-IP	12		Bernard Mulligan/Christina Kyriakopoulou	F4	
		2.1.2-3	Preparing for the future research and innovation activities in systems medicine	CA	3		Bernard Mulligan/Christina Kyriakopoulou	F4	
	2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN DEVELOPMENT AND AGEING	2.2.1. Brain and related disorders		CLOSED					
	2.2.2. Human development and ageing	2.2.2-1	Integrative systems biology and comparative genomics for studying human ageing and/or most common age-related diseases	CP-SME	6	SME (30%)	Beatrice Lucaroni	F2	
		2.2.2-2	Investigator-driven clinical trials for optimisation of management of elderly patients with multiple diseases	CP-SME	6	SME (15%)	Beatrice Lucaroni	F2	
	2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES	2.3.0 Cross cutting	2.3.0-1	Diagnostics for infectious diseases in humans	CP-SBIR like	6	SME (50%)	Christian Desaintes/Arjon Van Hengel	F3
			2.3.0-2	ERA-NET on infectious disease	CA	2		Arjon Van Hengel	F3
		2.3.1. Anti-microbial drug res		CLOSED					
		2.3.2. HIV/AIDS, TB, Malaria	2.3.2-1	Co-infection of HIV/AIDS, malaria, tuberculosis and/or hepatitis	CP-FP	6		Hannu Laang	F3
			2.3.2-2	Co-morbidity between infectious and non-communicable diseases	CP-FP	6		Ole Olesen	F3
			2.3.2-3	Prevention and treatment for HIV/AIDS, malaria and tuberculosis	CP-SME	6	SME (15%)	Alessandra Martini	F3
			2.3.2-4	Low-cost interventions for disease control in resource poor settings	CP-FP	3		Inmaculada Penas Jimenez	F3
		2.3.3. Emerging epidemics		CLOSED					
	2.3.4. Neglected diseases		CLOSED						
	2.4. TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES	2.4.1. Cancer		CLOSED					
		2.4.2. Cardio-vascular diseases		CLOSED					
2.4.3. Diabetes and obesity		2.4.3-1	Innovative approaches to manage diabetes	CP-SME	6	SME (30%)	Nathalie Vercruysse	F2	
		2.4.3-2	Investigator-driven clinical trials for type 1 diabetes research	CP-FP	6		Nathalie Vercruysse	F2	
2.4.4. Rare diseases		2.4.4-1	Preclinical and/or clinical development of substances with a clear potential as orphan drugs	CP-FP-Industry	6	Industry (30%)	Catherine Berens	F5	
		2.4.4-2	Observational trials in rare diseases	CP-FP	3		Catherine Berens	F5	
		2.4.4-3	Best practice and knowledge sharing in the clinical management of rare diseases	CA	2		Catherine Berens	F5	
2.4.5. Other chronic diseases	2.4.5-1	Technological approaches to combating sensory impairments	CP-SBIR like	6	SME (50%)	Grigorij Kogan	F2		
	2.4.5-2	Biomarkers and diagnostics for chronic inflammatory diseases of the joints and/or digestive system	CP-SME	6	SME (15%)	Grigorij Kogan	F2		
P I L L A R 3	3.1. TRANSLATING RESULTS OF CLINICAL RESEARCH OUTCOME INTO CLINICAL PRACTICE		CLOSED						
	3.2. QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS	3.2-1	Improving the organisation of health service delivery	CP-FP	3		Kevin McCarthy	F3	
		3.2-2	New methodologies for health technology assessment	CP-FP	3		Fergal Donnelly	F3	
		3.2-3	Social innovation for ageing research	CP-FP	3		Kevin McCarthy	F3	
3.3. HEALTH PROMOTION AND PREVENTION		CLOSED							
3.4. INTERNATIONAL PUBLIC HEALTH & HEALTH SYSTEMS	3.4-1	Health systems/services research in low and middle income countries	CP-FP-SICA	6		Franklin Mamo	F3		
P I L L A R 4	4.1 ACROSS THE THEME	4.1-1	Network to encourage knowledge transfer activity in FP-funded health research	CA	2		Antoine Mialhe	F4	
		4.1-2	Training actions linked to intellectual property rights management and knowledge transfer	CA	2		Antoine Mialhe	F4	
		4.1-3	Support for presidency events	SA	0,1		Stéphane Hogan	F1	
		4.1-4	Communicating the benefits of European research to the general public	SA	0,5		Stéphane Hogan	F1	
		4.1-5	Preparing the future for emerging health research and innovation	SA	1		Olivier Le Dour	F1	
		4.1-6	Setting health-related development goals beyond 2015	CA	2		Ana Nieto Nuez	F3	
4.2. RESPONDING TO EU POLICY NEEDS		CLOSED							

Total number of topics: 38